Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEMADRIN vs TRIHEXYPHENIDYL HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.
Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.
Adjunctive treatment of Parkinson's disease,Drug-induced extrapyramidal reactions (acute dystonic reactions, parkinsonism, akathisia)
Adjunctive therapy for all forms of Parkinson's disease,Treatment of drug-induced extrapyramidal symptoms (e.g., neuroleptic-induced parkinsonism, acute dystonia, akathisia)
2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.
1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.
6-10 hours in adults (terminal elimination half-life); may be prolonged in elderly or renal impairment.
10-17 hours; clinical context: steady-state concentrations achieved in 2-3 days.
Primarily metabolized by hepatic microsomal enzymes; metabolites are excreted in urine.
Primarily metabolized by hepatic microsomal enzymes, with CYP2D6 possibly involved. Elimination half-life is approximately 3–4 hours.
Primarily renal as unchanged drug and metabolites (approximately 50% unchanged); minor biliary/fecal elimination (<10%).
Renal (primarily as unchanged drug and metabolites; <15% unchanged) and biliary/fecal (minor).
~90%, primarily to albumin and alpha-1-acid glycoprotein.
Minimal; approximately 10-20% bound to plasma proteins (albumin).
4-8 L/kg; indicates extensive tissue distribution (high lipophilicity).
Approximately 0.5-1.5 L/kg; indicates extensive tissue distribution.
Oral: ~80% with first-pass metabolism reducing systemic exposure.
Oral: approximately 80-95% (first-pass metabolism minimal).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: administer every 6 hours. GFR <10 m L/min: avoid use or administer every 12 hours.
Cr Cl 10-50 m L/min: administer every 8-12 hours; Cr Cl <10 m L/min: consider alternative or reduce dose by 50%.
Contraindicated in severe hepatic impairment. In mild to moderate (Child-Pugh A or B): use with caution, reduce dose or extend dosing interval.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or use with extreme caution, reduce dose by 75%.
Not established. Safety and efficacy in children under 12 years have not been determined.
Children 2-12 years: initial 1 mg/day, increase by 1 mg every 3-5 days; maximum 6 mg/day in divided doses.
Initiate at low end of dosing range (2.5 mg once or twice daily); increase slowly. Monitor for confusion, urinary retention, constipation.
Start at 1 mg once or twice daily; increase slowly by 1 mg increments every 5-7 days; monitor for anticholinergic side effects.
None.
Not applicable.
May cause anticholinergic effects: confusion, hallucinations, urinary retention, constipation, blurred vision, heat stroke in hot weather,Use with caution in elderly patients due to CNS effects,Tardive dyskinesia: avoid abrupt withdrawal of antipsychotics when used for extrapyramidal symptoms,May exacerbate glaucoma, myasthenia gravis, gastrointestinal obstruction, and prostatic hypertrophy
May cause drowsiness, dizziness, or blurred vision; caution with driving or hazardous activities,Anticholinergic effects may be exacerbated in elderly patients, including confusion, constipation, urinary retention, and hyperthermia,Use cautiously in patients with glaucoma, prostatic hypertrophy, cardiac arrhythmias, or myasthenia gravis,Potential for abuse or dependence at high doses,May exacerbate tardive dyskinesia in patients on neuroleptics
Known hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders,Myasthenia gravis,Severe prostatic hypertrophy,Megaesophagus or esophageal achalasia
Hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders (e.g., pyloric stenosis, paralytic ileus),Severe ulcerative colitis or toxic megacolon,Myasthenia gravis
No significant food interactions are known. However, taking with food may reduce gastrointestinal upset. Avoid excessive consumption of anticholinergic-containing foods or beverages (e.g., certain teas) as it may potentiate side effects.
No significant food interactions. However, avoid excessive alcohol consumption as it may exacerbate CNS depression and anticholinergic effects. Maintain adequate hydration to prevent constipation and dry mouth.
Procyclidine (Kemadrin) is Pregnancy Category C. Animal studies are insufficient; no adequate human studies. First trimester: Avoid unless benefit outweighs risk; potential anticholinergic effects may cause fetal tachycardia. Second and third trimesters: Use with caution; neonatal anticholinergic effects (e.g., ileus, respiratory depression) reported near term.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.
Excretion into breast milk is unknown; M/P ratio not established. Due to potential anticholinergic effects (e.g., drowsiness, gastrointestinal disturbances) in the infant, avoid use during breastfeeding or use with caution. Monitor infant for anticholinergic side effects.
No data on M/P ratio; excreted in breast milk in unknown amounts. Caution recommended; avoid if possible.
No specific pharmacokinetic studies in pregnancy. Increased plasma volume and reduced gastrointestinal motility may alter absorption; however, no dose adjustment guidelines established. Use lowest effective dose. Monitor clinical response and adjust dosing based on anticholinergic side effects.
No established pharmacokinetic changes requiring dose adjustment; usual therapeutic dose maintained; monitor clinical response.
Kemadrin (procyclidine) is an anticholinergic agent used primarily for drug-induced parkinsonism and other extrapyramidal symptoms. Monitor for anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, and constipation. Use cautiously in elderly patients due to increased sensitivity. Avoid abrupt discontinuation to prevent withdrawal symptoms. May cause CNS effects such as dizziness or confusion.
Trihexyphenidyl is an anticholinergic agent used primarily for drug-induced parkinsonism and idiopathic Parkinson disease. It is less effective than levodopa but useful as adjunctive therapy. Onset of action is within 1 hour after oral administration; peak effect at 2-3 hours. Monitor for anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. Use with caution in elderly patients due to increased risk of confusion and falls. Abrupt withdrawal may precipitate parkinsonian crisis; taper gradually. Avoid in patients with narrow-angle glaucoma, myasthenia gravis, or gastrointestinal obstruction.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Report any vision changes, difficulty urinating, or severe constipation to your healthcare provider.,Use caution when driving or operating machinery until you know how this medication affects you.,Stay hydrated and use sugarless gum or hard candy to relieve dry mouth.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,This medication may cause dry mouth, blurred vision, constipation, or difficulty urinating.,Avoid alcohol and other CNS depressants as they may increase drowsiness and dizziness.,Use caution when driving or operating machinery until you know how this drug affects you.,Report any eye pain, vision changes, or difficulty passing urine to your healthcare provider.,Do not chew sustained-release capsules; swallow whole.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double doses.
No interactions on record
"Trihexyphenidyl, an anticholinergic agent, may potentiate the tachycardic effects of nabilone, a synthetic cannabinoid, due to additive inhibition of parasympathetic tone. This interaction can lead to clinically significant sinus tachycardia, palpitations, and potentially exacerbate underlying cardiovascular conditions such as coronary artery disease or arrhythmias."
"The concurrent use of trihexyphenidyl, an anticholinergic agent, with meperidine, an opioid analgesic, increases the risk of severe adverse effects such as central nervous system depression, respiratory depression, and anticholinergic toxicity (e.g., delirium, hyperthermia, and urinary retention). This additive pharmacodynamic interaction occurs due to combined anticholinergic and opioid properties, potentially leading to life-threatening outcomes, especially in elderly or debilitated patients. Clinicians should consider alternative therapies or closely monitor for signs of excessive sedation, respiratory compromise, and anticholinergic crisis."
"Donepezil, a cholinesterase inhibitor used in Alzheimer's disease, increases acetylcholine levels in the central nervous system. Trihexyphenidyl, an anticholinergic agent for Parkinson's disease, blocks muscarinic acetylcholine receptors. Concurrent use results in functional antagonism, where trihexyphenidyl's anticholinergic effects diminish the efficacy of donepezil, potentially worsening cognitive function in Alzheimer's patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEMADRIN vs TRIHEXYPHENIDYL HYDROCHLORIDE, answered by our medical review team.
KEMADRIN is a Anticholinergic Antiparkinsonian that works by Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.. TRIHEXYPHENIDYL HYDROCHLORIDE is a Anticholinergic Antiparkinsonian that works by Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEMADRIN and TRIHEXYPHENIDYL HYDROCHLORIDE depend on the specific clinical indication. These are both Anticholinergic Antiparkinsonian agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEMADRIN is: 2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.. The standard adult dose of TRIHEXYPHENIDYL HYDROCHLORIDE is: 1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEMADRIN and TRIHEXYPHENIDYL HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEMADRIN is classified as Category C. Procyclidine (Kemadrin) is Pregnancy Category C. Animal studies are insufficient; no adequate human studies. First trimester: Avoid unless benefit outweighs risk; potential anticho. TRIHEXYPHENIDYL HYDROCHLORIDE is classified as Category C. First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.